Premium
Dexfenfluramine in Type II diabetes: effect on weight and diabetes control
Author(s) -
Stewart Graeme O,
Stein Gary R,
Davis Timothy M E,
Findlater Peta
Publication year - 1993
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1993.tb121695.x
Subject(s) - dexfenfluramine , medicine , placebo , type 2 diabetes , triglyceride , weight loss , endocrinology , diabetes mellitus , overweight , obesity , body weight , cholesterol , fenfluramine , receptor , alternative medicine , pathology , serotonin
Objective To assess the effect of dexfenfluramine on weight loss, diabetic control and blood lipids in type II diabetics over a three‐month period. Design, setting and patients : Forty overweight patients in the Diabetic Clinic, Fremantle Hospital, were studied in a double‐blind, placebo‐controlled trial with a run‐in period of one month followed by three months on either dexfenfluramine or placebo. Main outcome measures : Changes in body weight, and fasting plasma glucose, glycosylated haemoglobin, plasma cholesterol and triglyceride levels. Main results : The median change in weight was ‐3.8 kg in the treatment group (Df) and +0.3 kg in the placebo group (PI) ( P = 0.006). The median changes in fasting plasma glucose levels were ‐1.0 mmol/L (Df) and +0.6 mmol/L (PI) P =0.010). The median changes in glycosylated haemoglobin levels were ‐1.4% (Df) and +0.2% (PI) ( P = 0.002). The median changes in triglyceride levels were ‐0.3 mmol/L (Df) and +0.2 mmol/L (PI) ( P = 0.017). Cholesterol level did not change significantly. Conclusion : Dexfenfluramine is effective in achieving weight loss and also improved diabetic control in obese type II diabetics over a three‐month period.